Perceived helpfulness of treatment for generalized anxiety disorder: a World Mental Health Surveys report.
Generalized anxiety disorder
Pathways to treatment
Patient-centered outcomes
Treatment helpfulness
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
31
01
2021
accepted:
07
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
27
8
2021
Statut:
epublish
Résumé
Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment. Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment. The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness. The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.
Sections du résumé
BACKGROUND
Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment.
METHODS
Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment.
RESULTS
The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness.
CONCLUSIONS
The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.
Identifiants
pubmed: 34372811
doi: 10.1186/s12888-021-03363-3
pii: 10.1186/s12888-021-03363-3
pmc: PMC8351147
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
392Subventions
Organisme : FIC NIH HHS
ID : R03 TW006481
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH060220
Pays : United States
Investigateurs
Sergio Aguilar-Gaxiola
(S)
Ali Al-Hamzawi
(A)
Mohammed Salih Al-Kaisy
(MS)
Jordi Alonso
(J)
Yasmin A Altwaijri
(YA)
Laura Helena Andrade
(LH)
Lukoye Atwoli
(L)
Corina Benjet
(C)
Guilherme Borges
(G)
Evelyn J Bromet
(EJ)
Ronny Bruffaerts
(R)
Brendan Bunting
(B)
Jose Miguel Caldas-de-Almeida
(JM)
Graça Cardoso
(G)
Somnath Chatterji
(S)
Alfredo H Cia
(AH)
Louisa Degenhardt
(L)
Koen Demyttenaere
(K)
Silvia Florescu
(S)
Giovanni de Girolamo
(G)
Oye Gureje
(O)
Josep Maria Haro
(JM)
Meredith G Harris
(MG)
Hristo Hinkov
(H)
Chi-Yi Hu
(CY)
Peter de Jonge
(P)
Aimee Nasser Karam
(AN)
Elie G Karam
(EG)
Norito Kawakami
(N)
Ronald C Kessler
(RC)
Andrzej Kiejna
(A)
Viviane Kovess-Masfety
(V)
Sing Lee
(S)
Jean-Pierre Lepine
(JP)
John J McGrath
(JJ)
Maria Elena Medina-Mora
(ME)
Zeina Mneimneh
(Z)
Jacek Moskalewicz
(J)
Fernando Navarro-Mateu
(F)
Marina Piazza
(M)
Jose Posada-Villa
(J)
Kate M Scott
(KM)
Tim Slade
(T)
Juan Carlos Stagnaro
(JC)
Dan J Stein
(DJ)
Margreet Ten Have
(M)
Yolanda Torres
(Y)
Maria Carmen Viana
(MC)
Daniel V Vigo
(DV)
Harvey Whiteford
(H)
David R Williams
(DR)
Bogdan Wojtyniak
(B)
Informations de copyright
© 2021. The Author(s).
Références
Contemp Nurse. 2015 Oct-Dec;51(2-3):107-20
pubmed: 26866531
Br J Psychiatry. 2010 Nov;197(5):378-85
pubmed: 21037215
J Affect Disord. 2021 Jun 1;288:199-209
pubmed: 33940429
JAMA Psychiatry. 2020 Aug 1;77(8):830-841
pubmed: 32432716
Depress Anxiety. 2020 Oct;37(10):972-994
pubmed: 32667096
Psychol Med. 2011 Aug;41(8):1751-61
pubmed: 21134315
J Consult Clin Psychol. 1993 Dec;61(6):952-65
pubmed: 8113496
J Anxiety Disord. 2007;21(5):662-76
pubmed: 17118626
World Psychiatry. 2019 Oct;18(3):276-285
pubmed: 31496102
Arch Psychiatr Nurs. 2014 Feb;28(1):43-9
pubmed: 24506986
Cogn Behav Ther. 2020 Jan;49(1):1-21
pubmed: 30760112
Int J Psychiatry Clin Pract. 2006;10 Suppl 1:16-21
pubmed: 24931539
JAMA Psychiatry. 2017 May 1;74(5):465-475
pubmed: 28297020
JAMA Psychiatry. 2020 Aug 1;77(8):784-786
pubmed: 32432693
Front Behav Neurosci. 2014 Apr 24;8:131
pubmed: 24795583
Int Clin Psychopharmacol. 2011 Mar;26(2):75-83
pubmed: 21102344
Clin Psychol Rev. 2007 Jun;27(5):572-81
pubmed: 17343963
Int J Methods Psychiatr Res. 2006;15(4):167-80
pubmed: 17266013
J Psychosom Res. 2007 Feb;62(2):189-95
pubmed: 17270577
Behav Cogn Psychother. 2017 Nov;45(6):647-660
pubmed: 28528592
JAMA Intern Med. 2018 Sep 1;178(9):1278-1280
pubmed: 30039169
Int J Methods Psychiatr Res. 2004;13(2):93-121
pubmed: 15297906
Psychol Med. 2005 Dec;35(12):1761-72
pubmed: 16300690
Trials. 2017 Mar 14;18(1):122
pubmed: 28288676
Depress Anxiety. 2008;25(1):72-90
pubmed: 17146763
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Mol Psychiatry. 2011 Dec;16(12):1234-46
pubmed: 20938433
Psychol Bull. 2005 Sep;131(5):785-95
pubmed: 16187860
Depress Anxiety. 2012 Jul;29(7):614-20
pubmed: 22495990
Am J Psychiatry. 2005 Jun;162(6):1179-87
pubmed: 15930067